Positioning no disclosures inside 60 days, left as found
Options put/call open interest 3.69, read 2026-11-03
Ethical passes the values gate
Price36.39 USD
Fair value36.50
Ethical score70.0/100
Value readFairas of 3 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup24.76+47.0% to today ✓Markdown gives way to Markup with deal news in the headlines
2026-10-02Read Markdown24.11+50.9% to today Accumulation gives way to Markdown after a 9% slide in 3 weeks
2026-09-09Read Accumulation26.47+37.5% to today ✓Distribution gives way to Accumulation
2026-08-08Read Distribution25.61+42.1% to today Markdown gives way to Distribution after an 11% rise in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Pacira BioSciences, Inc. holds its Markup at $36.39. The statistical read favours the buyers, held for 17 days.
As held on the ledger · 2026-11-03
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 17 days
Price at the screen
$36.39
Valuation
103.83 trailing · 10.51 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.25
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.06%
Below 33%
Interest-bearing debt is just 33.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.31%
Below 33%
Cash held in interest-bearing accounts and securities is 6.3% of assets, under the one-third limit.
Pass
Receivables
22.34%
Below 49%
Money owed to the company is 22.3% of assets, under the 49% limit.
Pass
Revenue purity
3.13%
Below 5%
Only 3.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Pacira BioSciences, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 33%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PCRX's ethical verdict changes
Today PCRX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades at roughly a 0% discount to our $36.50 fair value, 6.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 0.3% discount to the base estimate.
Where our models see it going: fair-value estimate $36.50, with a range of $36.50 to $72.78, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Non opioid pain relief looks cheap until margins appear
A patient reaching for relief after surgery wants something that works without the opioid risks. Pacira sells exactly that with its liposome injectable, yet the business delivers just 5% revenue growth and a 1% profit margin. At a forward multiple of 7 times earnings the shares trade well below our calculated value, but the thin returns on equity give little reason to step in.
We pass because the opportunity rating stays at none. Low single digit growth combined with almost invisible profitability points to a business that is not compounding capital or widening any moat. Analyst targets sit only modestly higher than the current price, reinforcing that the apparent discount reflects real operating weakness rather than a mispriced winner.
Risk sits in execution and competition that could keep margins compressed for years. Even an ethical screen pass does not turn poor returns into an investable story. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PCRX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$36.390.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$36.40+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$36.39+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$36.39+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$36.39+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$36.39+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$36.39+0.1%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$36.34+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 50% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter.
2026-10-18Markup$36.33+46.7%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 46.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29. Insiders have been net sellers over the past quarter.
2026-10-11Markup · changed$24.76+2.7%Entry 7
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (7 analysts) rates it buy, with a mean price target of $29.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.